To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Start Date10 Jun 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06998940

/ RecruitingPhase 3IIT

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

Start Date13 May 2026

Sponsor / Collaborator

SWOG

[+1]

NCT07172919

/ RecruitingPhase 2

A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study

The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.

Start Date02 Jan 2026

Sponsor / Collaborator

Amgen, Inc.

100 Clinical Results associated with Panitumumab

100 Translational Medicine associated with Panitumumab

100 Patents (Medical) associated with Panitumumab

2,241

Literatures (Medical) associated with Panitumumab

01 Aug 2026·Clinics and Research in Hepatology and Gastroenterology

Selective internal radiation therapy as a bridge to curative-intent surgery in bulky colorectal liver metastases

Article

Author: Casteillo, Francois ; El Boukili, Ilies ; Habouzit, Vincent ; Le Roy, Bertrand ; Mohamed, Soiwafi ; Grange, Rémi

Achieving secondary resectability remains a major challenge in patients with initially unresectable colorectal liver metastases (CRLM). We report a 46-year-old patient with rectal adenocarcinoma and three large synchronous unresectable liver metastases who achieved a durable response following an intensive multimodal strategy. FOLFOX plus panitumumab induced partial regression, while selective internal radiation therapy (SIRT) led to extensive tumor necrosis, enabling curative-intent extended left hepatectomy combined with microwave ablation. The patient remains in remission without systemic therapy more than six months after treatment completion. This case highlights the role of SIRT in conversion strategies for large oligometastatic CRLM.

01 Jun 2026·Data in Brief

Data on microRNA transcriptomic signatures, predicted gene targets and pathway analysis in response to cetuximab or panitumumab in colorectal cancer cells

Article

Author: Marouillat, Sylviane ; Lecomte, Thierry ; Hérault, Olivier ; Beilstein, Frauke ; Ibrahim, Sajida ; Corset, Laetitia ; Raoul, William ; Chautard, Romain ; Picou, Frédéric

Resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) is common in metastatic colorectal cancer (mCRC) and reliable predictive biomarkers remain lacking. The identification of new predictive biomarkers is therefore necessary to assess the efficacy of anti-EGFR mAb, in order to optimize the therapeutic strategy for mCRC. Micro-RNAs (miR) are small non-coding RNAs that primarily regulate gene expression, and whose dysregulation in anti-EGFR resistance has been widely reported in CRC. Following a previous analysis using a miRnome strategy, the present study focused on NGS (next-generation sequencing) to investigate a broader range of miRNAs. We identified several miR resistance signatures as well as potential target genes and associated pathways following exposure to different doses of cetuximab or panitumumab in colorectal cancer cells. In the context of the search for useful biomarkers for this cancer, this could help optimize the design of in vivo experiments or future prospective clinical trials.

01 Jun 2026·BIOMATERIALS

Antibacterial gradient-enhanced Janus self-pumping membrane for effective biofluid management and wound healing

Article

Author: Li, Ruyi ; Zhou, Jie ; Xu, Zhengyi ; Tan, Lin ; Cheng, Xinting ; Wang, Jian ; Cheng, Bin ; Zhu, Zhou ; Chen, Junyu ; Pei, Xibo ; Wan, Qianbing ; Zhao, Weifeng ; Wang, Xu

Optimal wound healing requires a sterile, moderately moist environment. Effective biofluid management is particularly crucial in infected skin defects, where complete drainage is essential for tissue repair. However, current dressings are largely designed for superficial injuries and fail to provide efficient fluid evacuation in deep wounds. In this study, we developed an antibiotic-loaded PAN/PCL dual-gradient Janus membrane comprising a hydrophobic macroporous outer layer, a hydrophilic microporous inner layer, and an intermediate transition layer. The membrane enables efficient self-pumping and unidirectional biofluid transport in superficial wounds. When curled into drainage strips, it enhances biofluid enrichment and supports gravity-resistant drainage in deep wounds. The superhydrophobic layer minimises cellular adhesion, reducing secondary trauma upon dressing removal. Sustained release of the incorporated antibiotic ensures prolonged antibacterial activity. In comparison with conventional clinical dressings, this Janus drainage system reduced local bacterial load by two orders of magnitude in a murine abscess model, significantly accelerating wound healing. Owing to its active drainage capacity, antibacterial efficacy, anti-adhesion properties, and biosafety, this system shows considerable potential for clinical management of infected wounds.

162

News (Medical) associated with Panitumumab

29 May 2026

·www.businesswire.com

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648-gene tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically Erbitux® (cetuximab) and Vectibix® (panitumumab). While xT CDx previously required a patient’s matched normal sample, this regulatory milestone allows the test to run as a tumor-only assay when a matched normal specimen (blood or saliva) is not viable or available. This approval paves the way for Tempus to migrate its entire DNA solid tumor portfolio to FDA-approved assays priced under its current ADLT (Advanced Diagnostic Laboratory Test) pricing. “This approval marks a milestone in both our regulatory and reimbursement strategy, as this allows the migration of our entire solid tumor DNA portfolio to be under unified ADLT pricing,” said Jim Rogers, Chief Financial Officer at Tempus. “As we have previously highlighted, we expect an estimated $200 ASP benefit beginning in 2027 as a result of this approval.” “Our goal is to support clinicians with advanced genomic profiling options,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “With FDA approval for both tumor-only and tumor-normal comprehensive genomic profiling, Tempus xT CDx provides flexibility for a range of clinical scenarios. While tumor-normal matched sequencing remains an important approach, we recognize that a matched sample is not always available, and now, patients can still benefit from an FDA-approved test that can help inform treatment decisions.” xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes in patients with previously diagnosed solid malignant neoplasms. The assay uses DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and, when available, patient-matched blood or saliva specimens. Additionally, the device detects microsatellite instability (MSI) status based on a genomic signature from the tumor specimen only. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. Click to view the complete xT CDx label, including companion diagnostic indications and important risk information. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding potential impact of xT CDx and other tests, the timing of the availability of such testing, and the potential financial impact of migrating our solid tumor portfolio to FDA approved assays. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Diagnostic ReagentsOligonucleotide

28 May 2026

·www.biospace.com

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying actionable biomarkers missed by genomic testing Presentations reinforce Guardant’s role advancing genomic and epigenomic profiling, characterizing tissue-free MRD and recurrence monitoring, and expanding biomarker-guided precision oncology PALO ALTO, Calif.--(BUSINESS WIRE)-- $GH --Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be presented include: Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval. “Our presence at this year’s ASCO reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum.” Key Guardant Health and collaborator presentations at ASCO 2026 Presentation Title Time / Location 8502 Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study May 29, 2026 / 1:00 - 4:00 PM CDT 3525 / 279 A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance) May 30, 2026 / 9:00 AM - 12:00 PM CDT 3546 / 313 A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS) May 30, 2026 / 9:00 AM - 12:00 PM CDT 3572 / 339 Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer May 30, 2026 / 9:00 AM - 12:00 PM CDT 3659 / 426 Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD) May 30, 2026 / 9:00 AM - 12:00 PM CDT 4050 / 33 Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA) May 30, 2026 / 9:00 AM - 12:00 PM CDT 4159 / 142 First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis May 30, 2026 / 9:00 AM - 12:00 PM CDT 4161 / 144 Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP May 30, 2026 / 9:00 AM - 12:00 PM CDT 4238 / 221 Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy May 30, 2026 / 9:00 AM - 12:00 PM CDT 3051 / 188 Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME) May 30, 2026 / 1:30 - 4:30 PM CDT 3052 / 189 Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study May 30, 2026 / 1:30 - 4:30 PM CDT 3070 / 207 Cell-free DNA methylation pro fusion epigenotyping to enhance ALK fusion detection in NSCLC patients May 30, 2026 / 1:30 - 4:30 PM CDT 3077 / 214 Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling May 30, 2026 / 1:30 - 4:30 PM CDT 3105 / 242 Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M) May 30, 2026 / 1:30 - 4:30 PM CDT 1031 / 145 Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer June 1, 2026 / 1:30 - 4:30 PM CDT 1095 / 209 Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i) June 1, 2026 / 1:30 - 4:30 PM CDT The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2026 can be found on the ASCO website . About Guardant360® Liquid CDx The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives. About Guardant360 Liquid Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts. About Guardant Reveal Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights. The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures. About Shield Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn , X (Twitter) and Facebook . Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Contacts Investor Contact: Zarak Khurshid investors@guardanthealth.com Media Contact: Meaghan Smith press@guardanthealth.com

ASCOPhase 2Phase 3Immunotherapy

19 May 2026

·www.biospace.com

HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy

HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead innate immunotherapy candidate into first-in-human studies Paris, France – May 19, 2026 – HEPHAISTOS-Pharma , a biopharmaceutical company developing next-generation innate immunotherapies for cancer, today announced the appointment of Stephan Braun as Chief Medical Officer . A seasoned oncology drug development leader, Stephan Braun brings extensive experience in translational and clinical development, with a strong track record in advancing innovative immuno-oncology programs from early development into clinical execution. He joins HEPHAISTOS-Pharma at a pivotal stage, as the company prepares the clinical development of its lead candidate, HEPHA440 , a 3rd generation TLR4 agonist small molecule designed for effective & safe cancer therapy. The appointment reflects growing recognition of HEPHAISTOS-Pharma’s scientific and therapeutic approach targeting Myeloid cells against solid tumors by a senior industry leader who recently contributed to the development success of ImCheck Therapeutics , one of Europe’s most visible immuno-oncology biotech companies. “ I am very pleased to join HEPHAISTOS-Pharma at such an important moment in its development ,” said Stephan Braun, Chief Medical Officer of HEPHAISTOS-Pharma . “ The company’s science is highly compelling, and its approach to innate immune activation has the potential to address a major unmet need in oncology. I look forward to working with the team to build a strong clinical development strategy and bring HEPHA440 closer to patients .” Stephan Braun’s appointment further strengthens a development organization recently reinforced with the addition of Frédérique Brune as Chief Development Officer and Delphine Brégeon as Head of CMC Operations . Together, the team brings complementary expertise across medical strategy, development execution, CMC, regulatory preparation and clinical readiness, positioning HEPHAISTOS-Pharma to advance HEPHA440 toward first-in-human studies. “We are very pleased to welcome Stephan in our team. Stephan’s appointment is a major milestone for HEPHAISTOS-Pharma,” said Frédéric Caroff, Chief Executive Officer of HEPHAISTOS-Pharma . “As we move closer to clinical development, we are strengthening the company with the expertise required to translate our science into a rigorous, patient-focused clinical strategy. Stephan brings exactly the combination of oncology experience, translational insight and clinical execution that we need at this stage.” As illustrated by the recent progress of companies such as ImCheck Therapeutics, immunomodulation is emerging as a key lever unlock the full potential of cancer immunotherapies. HEPHAISTOS-Pharma is pursuing this ambition by targeting Myeloid cells within the tumor microenvironment. HEPHA440 is specifically designed to activate the innate immune system while maintaining a high therapeutic index. As Chief Medical Officer, Stephan Braun will lead HEPHAISTOS-Pharma’s clinical development strategy, including the preparation of first-in-human studies, clinical trial design, translational development and medical strategy as the company advances toward clinical-stage execution. *** About HEPHAISTOS-Pharma HEPHAISTOS is a biopharmaceutical company developing 3rd generation innate immune boosters designed to convert myeloid-rich tumors into immunotherapy responsive tumors. The lead drug-candidate HEPHA440 has demonstrated compelling anti-tumor activity in a broad spectrum of preclinical models of cancers, both as single agent and in combination with other immunotherapies. The drug also demonstrated favorable tolerability and a broad therapeutic window predicting safe and efficacious systemic administration in humans. HEPHA440 is scheduled to enter clinical trials in 2027. About Stephan Braun, MD Dr. Stephan Braun is Chief Medical Officer of HEPHAISTOS Pharma, bringing extensive international experience in oncology drug development, clinical strategy and medical affairs. He previously served as Chief Medical Officer of ImCheck Therapeutics , where he contributed to the clinical development of ICT01 and to the momentum that ultimately led to the company’s acquisition by Ipsen. Earlier in his career, he held executive and leadership positions at CureTeq AG, Basilea , Ipsen , Parexel and Symphogen . At Amgen, he served as Medical Director of Clinical Development and Senior Medical Scientist, contributing to the development, approval and medical affairs activities of several drugs, including Aranesp, Xgeva and Vectibix. Dr. Braun also brings a strong academic background in oncology. From 1994 to 2008, he was a professor in the Department of Obstetrics and Gynecology at the medical universities of Munich and Innsbruck , where he built and led Breast Cancer Center and Gynecologic Oncology Center teams. He has authored 35 peer-reviewed publications and several book chapters in translational research and oncology, served on the editorial boards of several scientific journals, and is an active member of ASCO, AACR, ASH and ESMO. Attachment PR in English

Executive ChangeImmunotherapyAcquisitionAACR

100 Deals associated with Panitumumab

External Link

KEGG	Wiki	ATC	Drug Bank
D05350	Panitumumab	L01XC08	DB01269

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
KRAS G12C mutant Colorectal Cancer	United States	Amgen, Inc.	16 Jan 2025
KRAS Wild-type Colorectal Cancer	United States	Amgen, Inc.	23 May 2014
KRAS mutant Colorectal Cancer	Japan	Takeda Pharmaceutical Co., Ltd.	16 Apr 2010
RAS Wild Type Colorectal Cancer	Australia	Amgen Australia Pty Ltd.	14 May 2008
Metastatic Colorectal Carcinoma	United States	Amgen, Inc.	27 Sep 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma of large intestine	Phase 3	United States	Amgen, Inc.	27 Feb 2018
Colorectal Cancer, Hereditary Nonpolyposis, Type 1	Phase 3	United States	Amgen, Inc.	27 Feb 2018
NRAS Wild-type Colorectal Cancer	Phase 3	Japan	Takeda Pharmaceutical Co., Ltd.	29 May 2015
Metastatic Esophageal Squamous Cell Carcinoma	Phase 3	Germany	Amgen, Inc.	01 May 2012
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	-	Amgen, Inc.	01 May 2007
Advanced Colorectal Adenocarcinoma	Phase 3	-	Amgen, Inc.	01 Jun 2005
Brain Cancer	Phase 2	United States	Stanford University	01 Apr 2026
Advanced Malignant Solid Neoplasm	Phase 2	United States	Amgen, Inc.	02 Jan 2026
Advanced Malignant Solid Neoplasm	Phase 2	Japan	Amgen, Inc.	02 Jan 2026
Advanced Malignant Solid Neoplasm	Phase 2	Australia	Amgen, Inc.	02 Jan 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CR-SEQUENCE (ASCO2026)	Phase 3	RAS Wild Type Colorectal Cancer First line	418	FOLFOX+panitumumab followed by FOLFIRI+bevacizumab	ghntaezebd(wuumekwzeo) = pdtpqzyops mahnvdshoa (xkhtiqztmp ) View more	Negative	29 May 2026
				FOLFOX+bevacizumab followed by FOLFIRI+panitumumab	ghntaezebd(wuumekwzeo) = yinpjvhatd mahnvdshoa (xkhtiqztmp ) View more
C-PROWESS (ASCO2026)	Phase 2	Metastatic Colorectal Carcinoma RAS mutation status in circulating tumor DNA (ctDNA)	30	Panitumumab + irinotecan	qjtqxvdsre(hxhyzglllg) = ibzrqqtaef pkbgevobkk (rkixjewllo, 1.8 - 16.8) View more	Positive	29 May 2026
				Panitumumab + irinotecan (patients with none of these mutations (negative hyper-selection cohort))	qjtqxvdsre(hxhyzglllg) = qwyzgurdvt pkbgevobkk (rkixjewllo ) View more
AMNESIA-EGFR (ASCO2026)	Not Applicable	Gastroesophageal junction adenocarcinoma EGFR-amplified	130	Panitumumab	qygufzwnfo(ydntycxsdc) = bxquuzsulp svkelqqjrj (zyznvwurdi ) View more	Negative	29 May 2026
				Panitumumab (Lack of EGFR ampl)	jywsnclkjs(vpczcomlvk) = vijyrcwobl lusaukwllw (kwjrjcvzos ) View more
ASCO2026	Phase 2	Metastatic Colorectal Carcinoma ctDNA	38	Panitumumab with trametinib	pohepuwpwb(qhpsorjsmi) = hqbawtkexg giiskmpkma (tiuyggkqbj ) View more	Positive	29 May 2026
				Panitumumab monotherapy	pohepuwpwb(qhpsorjsmi) = kkuwujumjm giiskmpkma (tiuyggkqbj ) View more
NCT03693807 (CTgov)	Phase 2	Colorectal Liver Metastases \| Colorectal Cancer \| Bile Duct Neoplasms	35	Cetuximab+Gemcitabine+Floxuridine (FUDR)+Oxaliplatin+Irinotecan (CPT-11)+Panitumumab+Fluorouracil (Group 1: Unresectable Liver Metastases From Colorectal Cancer)	axdssnbiwa(slviuohkpy) = qyfrqrbemx eompvcguov (avewuhfqio, dcitezpnvo - xtqwiocbhi) View more	-	06 Feb 2026
				Cetuximab+Gemcitabine+Floxuridine (FUDR)+Oxaliplatin+Irinotecan (CPT-11)+Panitumumab+Fluorouracil (Group 2: Resectable Liver Metastases From Colorectal Cancer)	axdssnbiwa(slviuohkpy) = unvxnukikm eompvcguov (avewuhfqio, icgvtcytvr - erlbzxbfka) View more
NCT04587128 (ASCO_GI2026)	Phase 2	Metastatic Colorectal Carcinoma First line RAS/RAF wildtype	21	Panitumumab or Cetuximab	jysnxibqms(ucimichctx) = xdmwthhabw wujxvwwieb (zgauhteies ) View more	Positive	08 Jan 2026
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer First line	969	Panitumumab	jxdohusxjn(pxstpmuhmr) = unsclxdzru jwrctezlic (mjerwqttic, 23.68 - 38.12) View more	Positive	05 Dec 2025
				Cetuximab	jxdohusxjn(pxstpmuhmr) = tiqsbtedln jwrctezlic (mjerwqttic, 25.17 - 31.36) View more
NCT02593175 (CTgov)	Phase 2	Triple Negative Breast Cancer	43	Carboplatin+Paclitaxel+Panitumumab	xlwdfmvqmw = yzvrnhgfkv tbewpdoqnf (npgwpelwbe, bglabquluh - zakrtgrxca) View more	-	06 Nov 2025
NCT03584711 (OPTIPRIME, ESMO2025)	Phase 2	Metastatic Colorectal Carcinoma First line	118	FOLFOX plus PANITUMUMAB	xiuvtgxhut(uspivdaoiv) = pqhxxrlbhv ccpnyrjxvq (cmqcxnwzze, 19.3 - 28.3) View more	Positive	17 Oct 2025
NCT04787341 (PARERE, ESMO2025)	Phase 2	Metastatic Colorectal Carcinoma RAS \| BRAF wild-type	213	Panitumumab retreatment followed by regorafenib	ckqnwzhipx(tuvsptrcji) = sxvgkmzame kwjscdoszp (iudkpjnpkb )	Positive	17 Oct 2025
				Regorafenib followed by panitumumab	emawoqgmty(eoxipmleqi) = znefdgsedx piyuqcptau (legqsrnxem ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis